This Listing of Claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1. (previously presented): Substituted pyrazoline compounds of formula I,



I

wherein

R^1 represents hydrogen or a linear or branched C_{1-4}-alkyl group,

R^2, R^3 and R^4 independently of each other represent hydrogen, a linear or branched C_{1-6}-alkyl group, a linear or branched C_{1-6}-alkoxy group, a halogen atom, CH_2F, CHF_2, CF_3, CN, OH, NO_2, -(C=O)-R^8, SH, SR^8, SOR^8, SO_2R^8, NH_2, NHR^8, NR^8R^9, -(C=O)-NH_2, -(C=O)-NHR^8 or -(C=O)-NR^8R^9 whereby R^8 and R^9 for each substituent independently represent linear or branched C_{1-6} alkyl,

R^5 and R^6 independently of each other represent a linear or branched C_{1-6} alkyl group, a linear or branched C_{1-6}-alkoxy group, a halogen atom, CH_2F, CHF_2, CF_3, CN, OH, NO_2, -(C=O)-R^{10}, SH, SR^{10}, SOR^{10}, NH_2, NHR^{10}, $NR^{10}R^{11}$, -(C=O)-NH_2, -(C=O)-NHR^{10} or -(C=O)-$NR^{10}R^{11}$, whereby R^{10} and optionally R^{11} for each substituent independently represent linear or branched C_{1-6} alkyl;

R^7 represents hydrogen, a linear or branched C_{1-6}-alkyl group, a linear or branched C_{1-6}-alkoxy group, a halogen atom, CH_2F, CHF_2, CF_3, CN, OH, NO_2, -(C=O)-R^{10}, SH, SR^{10}, SOR^{10}, NH_2, NHR^{10}, $NR^{10}R^{11}$ -(C=O)-NH_2, -(C=O)NHR^{10} or -(C=O)-$NR^{10}R^{11}$, whereby R^{10} and optionally

R^{11} for each substituent independently represent linear or branched C_{1-6} alkyl;

with the proviso that

if R^1 and R^7 are H and R^5 and R^6 both represent Cl in the 3- and 4-position of the phenyl ring neither of R^2, R^3 and R^4 may represent F in the 4-position of the phenyl ring if the other two of R^2, R^3 and R^4 both represent H;

optionally in a form of one of its stereoisomers or a racemate or in a form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, or a corresponding solvate thereof.

2. (original): Compounds according to claim 1, characterized in that at least one of R^2, R^3 or R^4 represents hydrogen, while at least one of R^2, R^3 or R^4 is different from hydrogen.

3. (previously presented): Compounds according to claim 1, characterized in that R^7 represents hydrogen.

4. (previously presented): Compounds according to claim 1, characterized in that R^2, R^3 and R^4 independently of each other represent hydrogen, a linear or branched C_{1-6}-alkyl group, a halogen atom, or CF_3.

5. (previously presented): Compounds according to claim 1, characterized in that R^5 and R^6 independently of each other represent a linear or branched C_{1-6}-alkyl group, a halogen atom, or CF_3.

6. (previously presented): Compounds according to claim 1, characterized in that R^2 represents a chlorine atom in the 4-position of the phenyl ring, while R^3 and R^4 represent hydrogen.

7. (previously presented): Compounds according to claim 1, characterized in that R^5 and R^6 each represent chlorine atoms in the 2- and 4-position of the phenyl ring, while R^7 represents hydrogen.

8. (previously presented): Compounds according to claim 1, characterized in that R^1 represents hydrogen, methyl or ethyl.

9. (previously presented): Compounds of formula II according to claim 1



II

wherein

R^1 represents hydrogen or a linear or branched C_{1-4}-alkyl group,

R^{12} or R^{13} independently of each other represent a linear or branched C_{1-6}-alkyl group, a linear or branched C_{1-6}-alkoxy group, a halogen atom, CH_2F, CHF_2, CF_3, CN, OH, NO_2, SH, NH_2, hydrogen, methyl, ethyl, F, Cl, Br or CF_3,

R^{14} or R^{15} independently of each other represent a linear or branched C_{1-6}-alkyl group, a linear or branched C_{1-6}-alkoxy group, a halogen atom, CH_2F, CHF_2, CF_3, CN, OH, NO_2, SH, NH_2, methyl, ethyl, F, Cl, Br or CF_3,

optionally in a form of one of its stereoisomers or a racemate or in a form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, or a corresponding solvate thereof.

10. (previously presented): Compounds according to claim 9 characterized in that R^{12} and R^{13} independently of each other represent hydrogen, a linear or branched C_{1-6}-alkyl group, a halogen atom, or CF_3.

11. (previously presented): Compounds according to claim 9, characterized in that R^{14} and R^{15} independently of each other represent a linear or branched C_{1-6}-alkyl group, a halogen atom, or CF_3.

12. (previously presented): Compounds according to claim 9, characterized in that R^{13} represents Cl and R^{12} represents hydrogen.

13. (previously presented): Compounds according to claim 9, characterized in that R^{14} and R^{15} each represent Cl.

14. (previously presented): Compounds according to claim 9, characterized in that R^1 represents hydrogen, methyl or ethyl.

15. (previously presented): A compound according to claim 1 which is:

5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-carboxylic acid,

optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate.

16. (currently amended): Combination of compounds comprising at least one substituted pyrazoline compound of formula I of claim 1



I

~~wherein~~

~~R^1 represents hydrogen or a linear or branched C_{1-4}-alkyl group,~~

~~R^2, R^3 and R^4 independently of each other represent hydrogen, a linear or branched C_{1-6}-alkyl group, a linear or branched C_{1-6}-alkoxy group, a halogen atom, CH_2F, CHF_2, CF_3, CN, OH, NO_2, (C=O) R^8, SH, SR^8, SOR^8, SO_2R^8, NH_2, NHR_8, NR^8R^9, (C=O) NH_2, (C=O) NHR^8 or (C=O) NR^8R^9 whereby R^8 and R^9 for each substituent independently represent linear or branched C_{1-6}-alkyl,~~

~~R^5, R^6 and R^7 independently of each other represent hydrogen, a linear or branched C_{1-6}-alkyl~~

~~group, a linear or branched C_{1-6}-alkoxy group, a halogen atom, CH_2F, CHF_2, CF_3, CN, OH, NO_2, $(C=O)R^{10}$, SH, SR^{10}, SOR^{10}, NH_2, NHR^{10}, $NR^{10}R^{11}$, $(C=O)NH_2$, $(C=O)NHR^{10}$ and or $(C=O)NR^{10}R^{11}$, whereby R^{10} and optionally R^{11} for each substituent independently represent linear or branched C_{1-6}-alkyl;~~

~~optionally in a form of one of the its stereoisomers, preferably enantiomers or diastereomers, or a racemate or in a form of a mixture of at least two of the its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, or a corresponding solvate thereof.~~

and at least one substituted pyrazoline compound of general formula X



X

wherein

R^{16} represents an optionally at least mono-substituted phenyl group,

R^{17} represents an optionally at least mono-substituted phenyl group,

R^{18} represents a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an $-NR^{19}R^{20}$-moiety,

R^{19} and R^{20}, identical or different, represent a hydrogen atom, an unbranched or branched,

saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system or bonded via a linear or branched alkylene group, an $-SO_2-R^{21}-$ moiety, or an $-NR^{22}R^{23}-$moiety, with the proviso that R^{19} and R^{20} do not identically represent hydrogen,

R^{21} represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system or bonded via a linear or branched alkylene group,

R^{22} and R^{23}, identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system or bonded via a linear or branched alkylene group,

optionally in a form of one of its stereoisomers or a racemate or in a form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, or a corresponding solvate thereof.

Claims 17-39 (canceled)

40. (withdrawn): Process for the manufacture of substituted pyrazoline compounds of formula I or II, wherein R^1 is hydrogen, according to claim 1, characterized in that at least one benzaldehyde compound of formula III



(III)

wherein R^2, R^3 and R^4 have the meaning according to claim 1, is reacted with a pyruvate compound of formula (IV)



(IV),

wherein G represents an OR group with R being a branched or unbranched C_{1-6} alkyl radical or G represents an O^-K group with K being a cation, to yield a compound of formula (V)



(V)

which is optionally isolated or optionally purified, and which is reacted with an optionally substituted phenyl hydrazine of formula (VI)



(VI)

or a corresponding salt thereof, wherein R^5, R^6 and R^7 have the meaning according to claim 1, under inert atmosphere, to yield a compound of formula (VII)



(VII)

wherein R^2, R^3, R^4, R^5, R^6 and R^7 have the meaning as given above, which is optionally isolated or optionally purified, and optionally esterified to an alkyl-ester if in the substituted pyrazoline compound of formula I according to claim 1 R^1 is a linear or branched C_{1-4}-alkyl group.

41. (withdrawn): Medicament comprising at least one substituted pyrazoline compound of formula I or II according to claim 1, and optionally one or more pharmaceutically acceptable excipients.

42. (withdrawn): Medicament comprising at least one substituted pyrazoline compound of general formula I



I

wherein

R^1 represents hydrogen or a linear or branched C_{1-4}-alkyl group,

R^2, R^3 and R^4 independently of each other represent hydrogen, a linear or branched C_{1-6}-alkyl group, a linear or branched C_{1-6}-alkoxy group, a halogen atom, CH_2F, CHF_2, CF_3, CN, OH, NO_2, -(C=O)-R^8, SH, SR^8, SOR^8, SO_2R^8, NH_2, NHR^8, NR^8R^9, -(C=O)-NH_2, -(C=O)-NHR^8 or -(C=O)-NR^8R^9 whereby R^8 and R^9 for each substituent independently represent linear or branched C_{1-6} alkyl,

R^5, R^6 and R^7 independently of each other represent hydrogen, a linear or branched C_{1-6}-alkyl group, a linear or branched C_{1-6}-alkoxy group, a halogen atom, CH_2F, CHF_2, CF_3, CN, OH, NO_2, -(C=O)-R^{10}, SH, SR^{10}, SOR^{10}, NH_2, NHR^{10}, $NR^{10}R^{11}$, -(C=O)-NH_2, -(C=O)-NHR^{10} or -(C=O)-$NR^{10}R^{11}$, whereby R^{10} and optionally R^{11} for each substituent independently represent linear or branched C_{1-6} alkyl;

optionally in form of one of its stereoisomers or a racemate or in a form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a corresponding N-oxide thereof, or a

physiologically acceptable salt thereof, or a corresponding solvate thereof;

and optionally one or more pharmaceutically acceptable excipients.

Claims 43-64 (canceled)

65. (withdrawn): A method for the regulation of triglyceride levels in the blood plasma or for the prophylaxis or treatment of disorders of the central nervous system, or of food intake disorders, , the method comprising administering one or more substituted pyrazoline compounds of claim 1 and optionally one or more pharmaceutically acceptable excipients.

Claims 66-86 (canceled)